Dr Anne Rogiers obtained her MD in 1994 at the Vrije Universiteit Brussel (VUB). In 1995 she started her training as a psychiatrist in CHU Brugmann. After obtaining her specialist degree in 2001, Dr Anne Rogiers worked at the St Jan Ziekenhuis in Brussels and at the “Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten” (FAGG). Dr Rogiers was appointed as a clinical expert and rapporteur at several occasions for the “Belgische Geneesmiddelen Commisie” as well as for the Committee of Human Medicinal Products (CHMP), Scientific Advisory Group and for the Committee for Orphan Medicinal Products (COMP) of the European Medicine Agency (EMA). Within this position, she was also alternate member of the Efficacy Working Party (EWP) and member of the Central Nervous group of the EWP. From 2012 until now she is appointed as Head of Clinic at the department of Psychiatrie of CHU Brugmann, were she is responsible of the "Neurocognitive Remediation Unit" and participates in the supervision and the lectures for trainees in Psychiatry. Dr Anne Rogiers is member of several national and international scientific societies including ASCO, EORTC Melanoma Group, the EORTC Quality of Life Group, l’Association Francophone de Remédiation Neurocognitive (AFRN) and Vlaamse Vereniging van Psychiaters. Since the past 10 years, Dr Rogiers has built up clinical and scientific experience in the field of psychiatry, psycho-oncology, and neuro-oncology as a clinician, as well a researcher. Within her clinical practice, she has built up a unique clinical experience in the psychotherapeutic treatment of some of the first advanced melanoma patients and survivors treated with immunotherapy, who were included in the clinical trials investigating immune and targeted therapy. The scope of her current research is the psychosocial and neurocognitive outcome and quality of life of advanced melanoma survivors treated with immune therapy. For the ongoing study, conducted at the department of Medical Oncology of UZ Brussels, she received a price of the “Foundation Brugmann” and presented the first results at ASCO Survivorship symposium in February 2018 and at ASCO SITC in March 2019. Dr Rogiers is also co-investigator of an ongoing study, investigating psycho-social outcome of survivors treated with ipilimumab, in collaboration with the Nationaal Kanker Instituut of the Netherlands. In addition she continuous her research on the quality of life in the field of Neuro-Oncology. In 2020 she obtained her PhD, entitled "Psychosocial and neurocognitive outcome and quality of life of advanced melanoma survivors treated with immune therapy" and was nomitated as clinical Professor at the VUB in February 2021.